Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GANX
Strong SellSinkerGain Therapeutics, Inc. · Healthcare · United States · $77M · Avg Vol: $770K/d
COMPANY DESCRIPTION
Gain Therapeutics, Inc. is a clinical-stage biotechnology company utilizing its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover novel allosteric regulators. This computational platform serves as a key competitive moat, identifying drug candidates for neurodegenerative diseases and lysosomal storage disorders. The company operates as a niche innovator at the intersection of artificial intelligence and drug discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1M | 55.2K | 0 | 0 | -60.6% | — | — | — | — |
| EPS | -0.41 | -0.65 | -0.89 | -0.61 | — | -0.50 | -0.50 | -0.55 | — |
| Shares | 42.7M | 42.7M | 27.1M | 42.1M | -1.4% | 43.6M | — | — | — |
| Debt | 1.3M | 1.0M | 0.7M | 0.7M | -16.9% | 0.6M | — | — | — |
| Equity | 18.9M | 12.6M | 7.3M | 18.6M | -0.6% | — | — | — | — |
| Op CF | -14.7M | -18.9M | -18.9M | -18.5M | — | -19.0M | — | — | — |
| Inv CF | -14.8M | 10.2M | 5.0M | 0 | — | — | — | — | — |
| Fin CF | -78.8K | 12.6M | 13.0M | 28.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GANX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc.(you) | $77M | 7 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 11 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 7 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%